Neovasc Provides Tiara™ Clinical Update.
Sep 12, 2017
NASDAQ, TSX: NVCN
VANCOUVER, Sept. 12, 2017 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death.
More details to: